Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Deli Therapeutics Inc
E-scape Bio Inc
GlaxoSmithKline Plc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
Leucine Rich Repeat Serine/Threonine Protein Kise 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Pipeline by Cerevel Therapeutics LLC, H2 2019
Pipeline by D. Western Therapeutics Institute Inc, H2 2019
Pipeline by Denali Therapeutics Inc, H2 2019
Pipeline by E-scape Bio Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Imago Pharmaceuticals Inc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Lead Discovery Center GmbH, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NeuBase Therapeutics Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Pipeline by Origenis GmbH, H2 2019
Pipeline by Voronoi, H2 2019
Dormant Projects, H2 2019